Abstract. Hepatocellular carcinoma (HCC) is a highly aggressive form of carcinoma with poor prognosis, and HCC-associated mortality primarily occurs due to migration and invasion of HCC cells. The manipulation of epigenetic proteins, such as BRD4, has recently emerged as an alternative therapeutic strategy. The present study aimed to investigate the novel mechanism of BRD4 involvement in the migration and invasion of HCC cells. Reverse transcription-quantitative polymerase chain reaction was used to assess BRD4 mRNA expression levels in HCC cell lines. This analysis demonstrated that BRD4 was significantly overexpressed in HCC cell lines compared with a human immortalized normal liver cell line. A short hairpin RNA (shRNA) was then used to suppress BRD4 expression in HCC cells, and resulted in impaired HCC cell proliferation, migration and invasion. When the HepG2 HCC cell line was treated with recombinant human sonic hedgehog (SHH) peptide, the migration and invasion capabilities of HepG2 cells that were inhibited by BRD4 silencing were restored. BRD4 induced cell migration and invasion in HepG2 cells through the activation of matrix metalloproteinase (MMP)-2 and MMP-9, mediated by the SHH signaling pathway. Taken together, the results of the present study demonstrated the importance of BRD4 in HCC cell proliferation and metastasis. Thus, BRD4 is a potential novel target for the development of therapeutic approaches against HCC.

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive carcinoma with a poor prognosis. To date, there is no effective treatment for this fatal disease. The manipulation of epigenetic proteins, such as BRD4, has recently emerged as an alternative therapeutic strategy. Our objective was to analyze the effect of BRD4 on the cell progression and chemoresistance of PDAC and the novel mechanisms involved. In the present study, we firstly revealed that the expression of BRD4 was significantly upregulated in PDAC cell lines, compared to that in human pancreatic duct epithelial cells. An in vitro assay showed that the suppression of BRD4 impaired PDAC cell viability and proliferation. Similarly, the tumor growth rate was also decreased in vivo after silencing of BRD4. Furthermore, we showed that the expression of BRD4 was increased after treatment with gemcitabine (GEM). Combination treatment of GEM and BRD4 silencing had a synergistic effect on the chemotherapeutic efficacy in the PANC-1 and MIAPaCa-2 cell lines, and significantly promoted apoptosis. In particular, we demonstrated that BRD4 activated the Sonic hedgehog (Shh) signaling pathway members in a ligand-independent manner in the PDAC cells. Together, our results indicate the important role of BRD4 in PDAC cell proliferation and chemoresistance and suggests that BRD4 is a promising target directed against the transcriptional program of PDAC.

Gastric cancer (GC), the second most common malignant cancer worldwide, gives rise to a number of cancer-associated fatalities annually. Accumulating evidence has shown that microRNAs (miRs) may serve as oncogenes or tumor suppressors in GC development. The aim of this study was to discover the expression, function and mechanism of miR-761 in GC progression. First, the findings revealed that the expression level of miR-761 was significantly decreased in GC cell lines and tissues. The functional studies showed that miR-761 in GC cells inhibited tumor proliferation and metastasis. In the mechanistic study, through an online database search and luciferase assay, Ras and Rab interactor 1 (RIN1), which has been demonstrated as an oncogene in various types of cancer, including GC, was identified as a target of miR-761. Notably, miR-761 expression was demonstrated to be negatively correlated with RIN1 mRNA levels in GC tissues. Simultaneously, overexpression of RIN1 partially rescued the inhibitory effect of miR-761 mimic in the GC cells. The present study provided new insights into the role of miR-761 in the progression of GC, and implicated the potential application of miR-761 in GC cell therapy.

Breast cancer is the second leading cause of cancer-associated mortality in females in the USA. Hsa-miR-599 was demonstrated to function as a tumour suppressor during cancer progression. However, the function and mechanism of the hsa-miR-599 in human breast cancer remain elusive. Thus, the aim of the present study was to investigate the potential role of hsa-miR-599 in breast cancer biology. The expression levels of hsa-miR-599 in 40 pairs of surgical specimens and human breast cancer cell lines were detected using quantitative polymerase chain reaction analysis. The overexpression of hsa-miR-599 was established by transfecting mimics into the MCF-7 and MDA-MB-231 cell lines. Cell counting kit-8, colony formation and transwell assays were used to investigate the potential function of hsa-miR-599 in MCF-7 and MDA-MB-231 cell lines. Luciferase assays combined with western blot analysis was performed to validate the regulation of a putative target of hsa-miR-599. The results demonstrated that hsa-miR-599 was downregulated in the breast cancer tissues and breast cancer cell lines. Overexpression of hsa-miR-599 was revealed to inhibit the viability and proliferation of cell in vitro and tumour growth in vivo. The results of the luciferase assay indicate that bromodomain containing 4 (BRD4) is a direct target of hsa-miR-599. Furthermore, the xenograft mouse model demonstrated that overexpressed hsa-miR-599 reduced BRD4 expression. These results suggest that hsa-miR-599 serves as an oncosuppressive microRNA that impairs breast cancer tumorigenesis and progression by directly targeting BRD4. Furthermore, increased BRD4 expression partially reversed the suppressive effect of hsa-miR-599. In conclusion, the results of the present study demonstrated that hsa-miR-599 suppressed breast cancer progression by downregulating BRD4. The overexpression of hsa-miR-599 may be considered as a novel therapeutic target for the treatment of patients with breast cancer.

Paclitaxel is the most frequently used therapy regimen for triple-negative breast cancer (TNBC). However, chemoresistance frequently occurs, leading to enhanced failure rates of chemotherapy in TNBC; therefore, novel biological therapies are urgently needed. Gambogic acid (GA) has potent anticancer effects and inhibits tumor growth in several types of human cancer. However, the effects of GA on paclitaxel-resistant TNBC remain unknown. In the present study, the Cell Counting Kit-8 assay was used to examine the effect of GA and/or paclitaxel on the viability of TNBC cells; flow cytometry was used to examine the effects of GA on cell apoptosis; and western blotting and reverse transcription-quantitative PCR were used to determine the effects of GA on the expression of sonic hedgehog (SHH) signaling pathway target genes. The present results indicated that GA significantly inhibited the viability and enhanced the rate of apoptosis in paclitaxel-resistant MDA-MB-231 cells via activating the SHH signaling pathway. In vivo experiments confirmed that GA treatment enhanced the sensitivity of MDA-MB-231 cells to paclitaxel via the SHH signaling pathway. In conclusion, the combination of GA with paclitaxel may increase the antitumor effects on paclitaxel-resistant TNBC via downregulating the SHH signaling pathway.

The incidence of thyroid cancer has increased the past few decades, the most frequent type has been identified to be the papillary thyroid carcinoma (PTC). Following thyroidectomy, radioiodine ablation treatment on PTC is routinely performed. However, many patients do not benefit from radioiodine therapy. Therefore, novel targeted therapies to suppress tumor growth and improve radioiodine uptake are required. La ribonucleoprotein domain family member (LARP)7 is a member of the LARP family and functions as a potential suppressor of the progression of carcinoma. In the present study, the expression status of LARP7 in PTC tissues and cell lines was investigated, and the cell viability, proliferation and apoptotic rate, radioiodine uptake ability of PTC cells with overexpression of LARP7 in vitro was determined. Expression levels of LARP7 were significantly downregulated in PTC tissues and cell lines. Overexpression of LARP7 inhibited the proliferation and increased the radioiodine uptake ability of PTC cells in vitro and inhibited the tumor growth in vivo. Furthermore, LARP7 overexpression inhibited the sonic hedgehog (SHH) signaling pathway and increased sodium/iodide symporter (NIS) expression. However, treatment with recombinant human SHH partially reduced radioiodine uptake ability and NIS expression induced by LARP7. In conclusion, LARP7 may act as a tumor suppressor in PTC by inhibiting the SHH signaling pathway and may be a promising therapeutic target in patients with PTC.

No abstract

L��� ���������� RNA� ����RNA�� ��� ������ L��� ���������� RNA� ����RNA�� ��� ������ RNA� ���R�� h�ve ���t���� ���e� �� the p����e����� �f v����u� ���e��e�. The p�e�e�t �tu�y ���e� t� ��ve�t���te the �eve�� ��� �������� �����f�����e �f ���RNA t�u���e up�e�u��te� �e�e 1 �TUG1� ��� ��R�145�5p �� p�t�e�t� w�th �h����� he��t f���u�e �CHF� ��� exp���e the�� ������t�ve v��ue �e������� ���e��e �eve��ty. TUG1 ��� ��R�145�5p �eve�� we�e �ete�te� by �eve��e�t�������pt��� qu��t�t�t�ve PCR. C���e��t���� we�e ex����e� u���� Pe�����'� ����e��t��� ����y���. Re�e�ve� �pe��t��� �h����te���t�� ����y��� w�� u�e� t� ev��u�te the �������t�� v��ue �f TUG1, ��R�145�5p ��� b���� ��t��u�et�� pept��e �BNP�. Su�v�v�� ����y��� w�� pe�f���e� by the K�p����Me�e� �eth��. C�x �e��e����� ����y��� w�� u�e� t� ev��u�te the p������t�� v��ue �f TUG1 ��� ��R�145�5p. The �eve�� �f ��te��euk���6 ��� tu��� �e������ f��t���α �� �e�u� we�e �ete�te� by ELISA. The �e�u�t� ������te� th�t TUG1 w�� up�e�u��te� ��� ��R�145�5p w�� ��w��e�u��te� �� p�t�e�t� w�th CHF ��� they we�e �e��t�ve�y ����e��te�. TUG1 ��� ��R�145�5p we�e �������te� w�th the �eft ve�t����e eje�t��� f���t��� ��� we�e �b�e t� ������te the �eve��ty �f CHF. Se�u� TUG1 ��� ��R�145�5p h�� � �e�t��� �������t�� v��ue ��� the ���b���t��� �f BNP, TUG1 ��� ��R�145�5p h�� h��h �������t�� ���u���y. TUG1 ��� ��R�145�5p we�e ����e�y ����� ���te� w�th �ve���� �u�v�v�� ��� ��y fu��t��� �� ���epe��e�t p������t�� b�����ke�� f�� p�t�e�t� w�th CHF. I� ����t���, TUG1 ��� ��R�145�5p �eve�� we�e ���ke��y ����e��te� w�th inflammation in CHF. Upregulated TUG1 and downregulated ��R�145�5p ��y ������te the �eve��ty �f CHF, ��y �e�ve �� �������t�� ��� p������t�� b�����ke�� ��� ��y be ��v��ve� �� CHF progression by regulating inflammatory responses.